Bringing Hope to Healthcare: Freenome Secures $254M in Funding for Groundbreaking Cancer Detection

Freenome, a rapidly advancing biotech company founded in 2014, is thrilled to announce a significant funding milestone, having raised an impressive $254 million in its latest financing round. This capital infusion is a vital addition to Freenome's ongoing mission to create innovative tools that empower individuals to prevent, detect, and treat disease. With a strong focus on early cancer detection, the company is leveraging its cutting-edge multiomics platform and advanced machine learning techniques to develop next-generation blood tests. The flagship test aims to identify early-stage colorectal cancer and advanced adenomas, providing patients with crucial early intervention options when outcomes are most favorable. To date, Freenome has raised more than $1.1 billion from a cohort of visionary investors, including Perceptive Advisors, RA Capital Management, Roche Venture Fund, Kaiser Permanente, Novartis, and the American Cancer Society’s BrightEdge Ventures. These partnerships underscore the confidence leading investors have in Freenome’s transformative approach to cancer diagnostics. The recent funding will accelerate the development and commercial launch of our cancer screening tests, while further expanding Freenome’s talent pool of passionate ‘Freenomers’—professionals dedicated to making a lasting impact on patients’ lives through collaboration and respect. As we continue to push the boundaries of innovation in healthcare, this investment not only reinforces our commitment to advancing early cancer detection but also solidifies Freenome's role as a pioneer in the biotech industry.